Year None2022202120202019201820172016 August 15, 2022 Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights Go to August 11, 2022 Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline Go to August 9, 2022 Medicenna Announces Pricing of US$20 Million Public Offering of Units Go to August 8, 2022 Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units Go to August 5, 2022 Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022 Go to July 27, 2022 Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study Go to Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Next page next › Last page last »
August 15, 2022 Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights Go to
August 11, 2022 Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline Go to
August 8, 2022 Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units Go to
August 5, 2022 Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022 Go to
July 27, 2022 Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study Go to
